Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01241721 · ClinicalTrials.gov registry record · NA

Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

A NA study of Breast Cancer and Breast Cancer Surgery, sponsored by Swedish Medical Center.

Completed
Registry status
NA
Development phase
34
Enrollment target
2
Study locations

NCT01241721 is a NA study of Breast Cancer and Breast Cancer Surgery that has completed, run by Swedish Medical Center. The registered enrollment target is 34 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01241721, a NA study of Breast Cancer and Breast Cancer Surgery, has completed, sponsored by Swedish Medical Center.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast-conserving surgery but identified to have a second unsuspected breast cancer by MRI.

Interventions

  • DEVICE Positron Emission Mammography (PEM)

Study Locations (2)

Washington

  • Swedish Cancer Institute - Seattle
  • Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center - Seattle

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2010-09
Est. Completion 2016-04
Phase NA

Sponsor

Swedish Medical Center

30 total trials

What the Registry Record Tells You About NCT01241721

The ClinicalTrials.gov registry entry for NCT01241721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Mammography (PEM) is the first listed.

NCT01241721 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01241721 about?

NCT01241721 is a clinical study titled "Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer". The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast-conserving surgery but ide...

What is the current status of trial NCT01241721?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2010-09. Estimated completion is 2016-04.

What conditions does trial NCT01241721 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Surgery.

What interventions are being tested in trial NCT01241721?

The interventions under investigation include: Positron Emission Mammography (PEM) (DEVICE).

Who is sponsoring clinical trial NCT01241721?

This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01241721 being conducted?

This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.